Research programme: reperfusion injury therapies - GENOPIA Biomedical

Drug Profile

Research programme: reperfusion injury therapies - GENOPIA Biomedical

Alternative Names: Reperfusion injury therapies research programme - GENOPIA Biomedical

Latest Information Update: 24 Feb 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GENOPIA Biomedical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Reperfusion injury; Stroke

Most Recent Events

  • 24 Feb 2010 Discontinued - Preclinical for Reperfusion injury in Germany (unspecified route)
  • 24 Feb 2010 Discontinued - Preclinical for Stroke in Germany (unspecified route)
  • 04 Aug 2004 Compounds are available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top